Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Richard P. Tobin, Kimberly R. Jordan, William A. Robinson, et al.
International Immunopharmacology (2018) Vol. 63, pp. 282-291
Open Access | Times Cited: 167

Showing 26-50 of 167 citing articles:

Increased incidence of venous thromboembolism with cancer immunotherapy
Joanna Roopkumar, Shadi Swaidani, Ann S. Kim, et al.
Med (2021) Vol. 2, Iss. 4, pp. 423-434.e3
Open Access | Times Cited: 96
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Cristina Zalfa, Silke Paust
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 71
Myeloid-Derived Suppressor Cells in Solid Tumors
Tianmiao Ma, Bernhard W. Renz, Matthias Ilmer, et al.
Cells (2022) Vol. 11, Iss. 2, pp. 310-310
Open Access | Times Cited: 66
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Keywan Mortezaee
Life Sciences (2021) Vol. 277, pp. 119627-119627
Closed Access | Times Cited: 64
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Shweta Joshi, Andrew B. Sharabi
Pharmacology & Therapeutics (2022) Vol. 235, pp. 108114-108114
Open Access | Times Cited: 57
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Richard P. Tobin, Dasha T. Cogswell, Victoria M. Cates, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 7, pp. 1209-1219
Closed Access | Times Cited: 53
MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets
Wanying Zhang, Xiangzhi Fang, Chenggang Gao, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 69, pp. 90-103
Open Access | Times Cited: 47
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Bin Wang, Han Yin, Yuyu Zhang, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Understanding the squamous cell carcinoma immune microenvironment
Vahide Saeidi, Nicole Doudican, John A. Carucci
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Md Aslam Hossain
International Immunopharmacology (2024) Vol. 143, pp. 113365-113365
Closed Access | Times Cited: 9
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Christiana M. Neophytou, Chryso Pierides, Maria Christodoulou, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 67
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Elisa Peranzoni, Vincenzo Ingangi, Elena Masetto, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 64
Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers
Hui Xuan Lim, Tae Sung Kim, Chit Laa Poh
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3599-3599
Open Access | Times Cited: 57
Rational targeting of immunosuppressive neutrophils in cancer
Yun Zhao, Sharif Rahmy, Zhongmin Liu, et al.
Pharmacology & Therapeutics (2020) Vol. 212, pp. 107556-107556
Closed Access | Times Cited: 56
Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer
Yuji Takeyama, Minoru Kato, Satoshi Tamada, et al.
Cancer Letters (2020) Vol. 479, pp. 89-99
Open Access | Times Cited: 52
A QSP model of prostate cancer immunotherapy to identify effective combination therapies
Roberta Coletti, Lorena Leonardelli, Silvia Parolo, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 51
Expansion of Myeloid Derived Suppressor Cells Contributes to Platelet Activation by L-Arginine Deprivation during SARS-CoV-2 Infection
Alessandra Sacchi, Germana Grassi, Stefania Notari, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 2111-2111
Open Access | Times Cited: 46
N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy
Julia R. Krug, Gabriele Rodrian, Katja Petter, et al.
Gastroenterology (2022) Vol. 164, Iss. 3, pp. 392-406.e5
Open Access | Times Cited: 35
Retinoids as anti-cancer agents and their mechanisms of action.
Ying Hua Jin, Soek Sin Teh, Harrison Lik Nang Lau, et al.
PubMed (2022) Vol. 12, Iss. 3, pp. 938-960
Closed Access | Times Cited: 30
Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer
Yun Liang, Wenshan Wang, Xiaojun Zhu, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 30
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Yan Zhao, Yuansong Bai, Meili Shen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Role of myeloid-derived suppressor cells in tumor recurrence
Kathryn Cole, Zaid Al‐Kadhimi, James E. Talmadge
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 1, pp. 113-142
Open Access | Times Cited: 19
Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity
Elliot D. Kramer, Scott I. Abrams
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 47
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
Yufei Wang, Anna Jia, Yujing Bi, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2626-2626
Open Access | Times Cited: 47
The emerging role of myeloid-derived suppressor cells in radiotherapy
Chang‐Hee Kang, Seong‐Yun Jeong, Si Yeol Song, et al.
Radiation Oncology Journal (2020) Vol. 38, Iss. 1, pp. 1-10
Open Access | Times Cited: 44

Scroll to top